PMID- 31882734
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20210110
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Dec 27
TI  - Applied Precision Cancer Medicine in Neuro-Oncology.
PG  - 20139
LID - 10.1038/s41598-019-56473-0 [doi]
LID - 20139
AB  - Brain tumours that are refractory to treatment have a poor prognosis and 
      constitute a major challenge in offering effective treatment strategies. By 
      targeting molecular alterations, precision cancer medicine may be a viable option 
      for the treatment of brain tumours. In this retrospective analysis of our PCM 
      platform, we describe the molecular profiling of primary brain tumours from 50 
      patients. Tumour samples of the patients were examined by a 161-gene 
      next-generation sequencing panel, immunohistochemistry, and fluorescence in situ 
      hybridization (FISH). We identified 103 molecular aberrations in 36 (72%) of the 
      50 patients. The predominant mutations were TP53 (14.6%), IDH1 (9.7%) and PIK3CA 
      (6.8%). No mutations were detected in 14 (28%) of the 50 patients. IHC 
      demonstrated frequent overexpression of EGFR and mTOR, in 38 (76%) and 35 (70%) 
      patients, respectively. Overexpression of PDGFRa and PDGFRb were less common and 
      detected in 16 and four patients, respectively. For 35 patients a targeted 
      therapy was recommended. In our database, the majority of patients displayed 
      mutations, against which targeted therapy could be offered. Based on our 
      observations, PCM may be a feasible novel treatment approach in neuro-oncology.
FAU - Taghizadeh, H
AU  - Taghizadeh H
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Comprehensive Cancer Center, Vienna, Austria.
FAU - Mullauer, L
AU  - Mullauer L
AD  - Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria.
FAU - Furtner, J
AU  - Furtner J
AD  - Comprehensive Cancer Center, Vienna, Austria.
AD  - Department of Biomedical Imaging and Image-guided Therapy, Medical University of 
      Vienna, Vienna, Austria.
FAU - Hainfellner, J A
AU  - Hainfellner JA
AD  - Comprehensive Cancer Center, Vienna, Austria.
AD  - Institute of Neurology, Medical University of Vienna, Vienna, Austria.
FAU - Marosi, C
AU  - Marosi C
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Comprehensive Cancer Center, Vienna, Austria.
FAU - Preusser, M
AU  - Preusser M
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of 
      Vienna, Vienna, Austria.
AD  - Comprehensive Cancer Center, Vienna, Austria.
FAU - Prager, G W
AU  - Prager GW
AD  - Department of Medicine I, Clinical Division of Oncology, Medical University of 
      Vienna, Vienna, Austria. gerald.prager@meduniwien.ac.at.
AD  - Comprehensive Cancer Center, Vienna, Austria. gerald.prager@meduniwien.ac.at.
LA  - eng
PT  - Journal Article
DEP - 20191227
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Disease Susceptibility
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Medical Oncology/methods
MH  - Nervous System Neoplasms/*diagnosis/etiology/*therapy
MH  - *Precision Medicine/methods
PMC - PMC6934769
COIS- M. Preusser has received honoraria for lectures, consultation or advisory board 
      participation from the following for-profit companies: Bayer, Bristol-Myers 
      Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, 
      Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck 
      Sharp & Dome. G.W. Prager received speaker's fees from Bayer, Roche, 
      Merck-Serono, Amgen, Servier, Celgene, Shire, MSD, Lilly, and Sanofi-Aventis. 
      M.K. received travel support from Merck, Bayer, Bristol-Myers Squibb, and Roche. 
      All other authors have nothing to declare.
EDAT- 2019/12/29 06:00
MHDA- 2020/11/18 06:00
PMCR- 2019/12/27
CRDT- 2019/12/29 06:00
PHST- 2019/05/17 00:00 [received]
PHST- 2019/11/25 00:00 [accepted]
PHST- 2019/12/29 06:00 [entrez]
PHST- 2019/12/29 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2019/12/27 00:00 [pmc-release]
AID - 10.1038/s41598-019-56473-0 [pii]
AID - 56473 [pii]
AID - 10.1038/s41598-019-56473-0 [doi]
PST - epublish
SO  - Sci Rep. 2019 Dec 27;9(1):20139. doi: 10.1038/s41598-019-56473-0.